<DOC>
	<DOCNO>NCT02077309</DOCNO>
	<brief_summary>Examination effect Linagliptin versus placebo 6 month vascular inflammation carotic artery abdominal adipose tissue inflammation patient diabetes mellitus type 2 . The effect assess FDG-PET scan . Furthermore effect Linagliptin vessel wall volume carotid artery assess MRI scan biomarkers vascular inflammation analyze blood sample .</brief_summary>
	<brief_title>Effect Linagliptin Vascular Inflammation Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>As part screen PET-CT scan execute examine baseline vascular inflammation carotid artery evaluate abdominal adipose tissue inflammation . Patients eligible participate study accord in- exclusion criterion randomise one two study arm . According randomisation patient receive 5 mg Linagliptin placebo per day period 6 month . To evaluate effect Linagliptin versus placebo vessel wall volume artery assess MRI scan vascular inflammation carotid artery FDG-PET , furthermore vascular inflammation analyze biomarkers blood sample abdominal adipose tissue inflammation investigate subcutaneous adipose tissue biopsy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>1 . Diabetes mellitus Type 2 2 . HbA1c &gt; 7 % 3 . Age &gt; 50 year 4 . Coronary artery disease carotid artery disease 5 . 18FFDG uptake carotid arterial wall background ( blood ) ratio &gt; 1.8 6 . Written inform consent prior study participation 7 . Stable antidiabetic cholesterol lower medication last 3 month 8 . Stable antidiabetic medication last 6 week include maximal tolerate dose metformin ( unless contraindication intolerance metformin exist ) ; 9 . Indication increase antidiabetic medication judge investigator 1 . Diabetes mellitus type 1 2 . Use DPP4 Inhibitor , GLP1 agonists , Thiazolindinedione 3 . Kidney disease CKD 4 ( GFR &lt; 30 ml/min/1.73 ) 4 . Liver disease ( ALT AST &gt; 3 time upper limit norm ) know liver cirrhosis 5 . Any reason able sustain image study 6 . Pacemaker/ICD/metallic clip close relation vessel brain 7 . Uncontrolled thyroid disease 8 . Active malignant disease 9 . Chronic inflammatory disease 10 . Chronic use NSAR cortison 11 . HbA1c &gt; 8.5 % 12 . Recent ( &lt; 3 month ) clinically significant coronary cerebral vascular event 13 . Pregnant female determine positive [ serum urine ] HCG test Screening prior dose 14 . Lactating female 15 . The subject history illness , , opinion Investigator , might pose unacceptable risk administer study medication 16 . The subject receive investigational drug within 30 day prior inclusion study 17 . The subject current past medical condition and/or require medication treat condition could affect evaluation study 18 . The subject unwilling unable follow procedure outline protocol 19 . The subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>T2DM ,</keyword>
	<keyword>vascular inflammation ,</keyword>
	<keyword>18-FDG-PET ,</keyword>
	<keyword>plaque morphology ,</keyword>
	<keyword>MRI ,</keyword>
	<keyword>DPP-4 Inhibition</keyword>
</DOC>